A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Clinical Pharmacokinetics

Volumn 56, Issue 5, 2017, Pages 551-559

  Heise, Tim ^a   Pieber, Thomas R ^b   Danne, Thomas ^c   Erichsen, Lars ^d   Haahr, Hanne ^d  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Children's Hospital Auf der Bult   (Germany)

^d NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; META ANALYSIS; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN ASPART; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85012932025     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-017-0514-8     Document Type: Article

References (29)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
3. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280–5.
4. 1c. Diabetes Care. 2003;26:881–5.
5. Mitrakou A, Kelley D, Mokan M. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22–9.
6. Heise T. Getting closer to physiologic insulin secretion. Clin Ther. 2007;29:S161–5.
7. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6:728–42.
8. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–8.
9. Hermansen K, Bohl M, Schioldan AG. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs. 2016;76:41–74.
10. US Food and Drug Administration. Inactive ingredient search for approved drug products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed 26 Jan 2017.
11. Buckley ST, Kildegaard J, Høiberg-Nielsen R, et al. Mechanistic analysis into the mode(s) of action of niacinamide in faster-acting insulin aspart. Diabetes Technol Ther. 2016;18(Suppl 1):A116–7.
12. Fath M, Danne T, Biester T, et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017. doi:10.1111/pedi.12506.
13. Heise T, Stender-Petersen K, Hövelmann U, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clinical Pharmacokinet. 2016. doi:10.1007/s40262-016-0473-5.
14. Heise T, Hövelmann U, Zijlstra E, et al. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017;34(1):29–38.
15. Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–8.
16. Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B Methodol. 1954;16:175–85.
17. ® 1 trial. Diabetes. 2016;65(Suppl. 1):A77.
18. ® 2 trial. Diabetes. 2016;65(Suppl. 1):A63.
19. Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173–7.
20. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33:2152–5.
21. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther. 1995;58:459–69.
22. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137–42.
23. Jørgensen LN, Nielsen FS. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia. 1990;33(Suppl. 1):A116.
24. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015;38:1008–15.
25. Heise T, Haahr H, Jensen L, et al. Faster-acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM). Diabetes. 2014;63(Suppl. 1):A34.
26. Jain L, Parks MH, Sahajwalla C. Determination of time to onset and rate of action of insulin products: importance and new approaches. J Pharm Sci. 2013;102:271–9.
27. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9:746–53.
28. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51:1790–5.
29. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.